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Abstract
Objective: Co-stimulatory and co-inhibitory molecules are mainly expressed on T cells and antigen presenting cells and
strongly orchestrate adaptive immune responses. Whereas co-stimulatory molecules enhance immune responses, signaling
via co-inhibitory molecules dampens the immune system, thereby showing great therapeutic potential to prevent
cardiovascular diseases. Signaling via co-inhibitory T cell immunoglobulin and ITIM domain (TIGIT) directly inhibits T cell
activation and proliferation, and therefore represents a novel therapeutic candidate to specifically dampen pro-atherogenic
T cell reactivity. In the present study, we used an agonistic anti-TIGIT antibody to determine the effect of excessive TIGIT-
signaling on atherosclerosis.
Methods and Results: TIGIT was upregulated on CD4+ T cells isolated from mice fed a Western-type diet in comparison with
mice fed a chow diet. Agonistic anti-TIGIT suppressed T cell activation and proliferation both in vitro and in vivo. However,
agonistic anti-TIGIT treatment of LDLr2/2 mice fed a Western-type diet for 4 or 8 weeks did not affect atherosclerotic lesion
development in comparison with PBS and Armenian Hamster IgG treatment. Furthermore, elevated percentages of
dendritic cells were observed in the blood and spleen of agonistic anti-TIGIT-treated mice. Additionally, these cells showed
an increased activation status but decreased IL-10 production.
Conclusions: Despite the inhibition of splenic T cell responses, agonistic anti-TIGIT treatment does not affect initial
atherosclerosis development, possibly due to increased activity of dendritic cells.
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Introduction
Atherosclerosis, a chronic autoimmune-like disease, results from
imbalanced pro- and anti-inflammatory responses, resulting in
infiltration of inflammatory cells in the vessel wall. This results in
the formation of an atherosclerotic plaque and eventually causes
plaque rupture. Immune responses are regulated by a network of
costimulatory and coinhibitory molecules present on T cells and
antigen presenting cells (APCs), such as macrophages and
dendritic cells. The immune system provides a large diversity of
costimulatory and coinhibitory pathways and each pathway has its
own unique effect on the fate of individual immune cells.
Costimulatory signals can promote T cell survival, cell cycle
progression and differentiation to effector and memory T cells,
whereas coinhibitory molecules can terminate these processes
directly or indirectly via for example the induction of regulatory T
cells (Tregs).
A new-emerging complex network of costimulatory and
coinhibitory molecules is formed by T cell immunoreceptor with
Ig and ITIM domains (TIGIT, Vstm3, WUCAM), CD226
(DNAM-1), CD112 (PVRL2, nectin-2), and the poliovirus
receptor (PVR, CD155). TIGIT is expressed on different subsets
of T cells, including Tregs, activated CD4+ T cells, CD8+ T cells,
and on NK cells and NKT cells. PVR is highly expressed on DCs,
fibroblasts, endothelial cells and some tumor cells. [1,2] Signaling
through the TIGIT-PVR pathway can inhibit T cell responses in a
cell-intrinsic manner by directly targeting the TCR signaling
cascade as well as via the induction of tolerogenic DCs that
produce increased levels of IL-10. [3,4,5] In addition, TIGIT
engagement may modulate DC responses by influencing ERK
activity. [5] TIGIT can also bind to CD112 present on APCs
while PVR can also bind to CD226 present on T cells. TIGIT and
CD226 share common binding sites on PVR and CD112 and are
therefore cross-competing for binding to PVR and CD112. [3]
Several studies showed that CD226 is associated with costimula-
tory T cell signals, as it was capable to induce Th1 responses.
[6,7,8] Since TIGIT and CD226 compete for PVR binding, it is
also believed that TIGIT attenuates T cell responses by
interference of the CD226-mediated costimulation [3].
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e83134
Interference in this pathway by using TIGIT deficient mice has
been shown to aggravate EAE through elevated secretion of
proinflammatory cytokines such as IL-6, IFN-c and IL-17, and by
increased T cell proliferation. [4] In line with this finding, Levin
et al. showed that TIGIT overexpression reduces the development
of EAE. [3] Furthermore, soluble TIGIT inhibits collagen-induced
arthritis by dampening CD4+ T cell responses and by interfering
with CD226-mediated costimulation. Additionally, blocking
TIGIT accelerated mortality in a mouse model of graft versus
host disease [3].
To date, the role of the coinhibitory TIGIT-PVR axis in
atherosclerosis has not been explored. In the present study, we
therefore treated LDLr2/2 mice with an agonistic anti-TIGIT




Female LDLr deficient (LDLr2/2) mice, 10–12 weeks old, were
obtained from Jackson Laboratories. The animals were kept under
standard laboratory conditions and were fed a normal chow diet
or a Western-type diet containing 0.25% cholesterol and 15%
cocoa butter (Special Diet Services, Witham, Essex, UK). Diet and
water were provided ad libitum. All animal work was approved by
the regulatory authority of Leiden University and carried out in
compliance with the Dutch government guidelines.
TIGIT Expression on CD4+ T cells under
Hypercholesterolemic Conditions
Splenocytes were isolated from LDLr2/2 mice fed a Western-
type or chow diet. Single cell suspensions were obtained by
squeezing the organs through a 70 mm cell strainer. Red blood
cells were removed using erythrocyte lysis buffer (0.15 M NH4Cl,
10 mM NaHCO3, 0.1 mM EDTA, pH 7.3). Subsequently, CD4
+
T cells (.95% purity) were isolated by using the BD IMagTM
mouse CD4 T lymphocyte enrichment set according to the
manufacturer’s protocol (Beckton Dickinson, Mountain View,
CA). After the isolation the CD4+ cells were stained with a
fluorescent antibody for CD4 and TIGIT (clone 1G9). FACS
analysis was performed on a FACSCantoII (Beckton Dickinson,
Mountain View, CA). Data were analyzed using FACSDiva
software (Beckton Dickinson).
Functionality of the TIGIT Agonist under
Hypercholesterolemic Conditions
Agonistic anti-TIGIT antibody was kindly provided by N.
Joller. [4] To investigate the effect of agonistic anti-TIGIT on
splenocyte activation and proliferation under hypercholesterol-
emic conditions, splenocytes from Western-type diet fed mice
(n = 3) were cultured for 48 hours at 37uC in triplicate in a 96-wells
round-bottom plate (26105 cells/well) in RPMI 1640 supple-
mented with L-Glutamine, 100 U/mL streptomycin/penicillin
and 10% FCS. Splenocytes were stimulated with aCD3 and
aCD28 (2 mg/mL) in the presence of different concentrations of
agonistic anti-TIGIT (0–30 mg/mL) or hamster IgG (30 mg/ml).
Activated T cells (CD4+CD25int or CD4+CD62Llow) were
determined with FACS as described above. Proliferation was
measured by addition of 3H-thymidine (0.5 mCi/well, Amersham
Biosciences, The Netherlands) 16 hours prior to cell lysis. The
amount of 3H-thymidine incorporation was measured using a
liquid scintillation analyzer (Tri-Carb 2900R). Responses are
expressed as stimulation index (SI): ratio of mean counts per
minute of quintuplicate cultures with aCD3/aCD28 stimulation
to quintuplicate cultures without stimulation. To detect IL-2 in the
supernatant of splenocytes, an ELISA was performed according to
manufacturer’s protocol (eBioscience, Vienna). Absorbance was
measured at 450 nm.
Atherosclerosis
Atherosclerosis was induced in LDLr2/2 mice by feeding a
Western-type diet for 4 and 8 weeks. Mice were treated i.p. with
100 mg agonistic anti-TIGIT antibody (n = 9 and n = 12, respec-
tively), 100 mg hamster IgG (Innovative Research, n = 8 and
n = 12, respectively) or sterile PBS (n = 9 and n = 11, respectively)
at day 0, 2, 4, 10, 17 and 24 after start of Western-type diet. At
week 4 and week 8 mice were sacrificed and tissues were harvested
after in situ perfusion using PBS. Tissues for histology were fixated
in Zinc Formal-Fixx (Shandon Inc. Pittsburg, USA).
Serum Cholesterol Levels
During the experiments, mice were weighed and blood samples
were obtained by tail vein bleeding. The total cholesterol levels in
serum were determined at week 0 and 4 after start of the 4 week
experiment and at week 0, 2, 4, 6 and 8 after start of the 8 week
experiment. The concentration of serum cholesterol was deter-
mined using enzymatic colorimetric procedures (Roche/Hitachi,
Mannheim, Germany). Precipath (Roche/Hitachi) was used as an
internal standard.
Histological Analysis and Morphometry
Cryosections of the aortic root (10 mm) were made and stained
with Oil-red-O. Lesion collagen content was determined with a
Masson’s Trichrome staining. Furthermore, corresponding sec-
tions on separate slides were stained immunohistochemically with
an antibody directed against a macrophage specific antigen
(Moma-2, monoclonal rat IgG2b, diluted 1:1000). Goat anti-rat
IgG alkaline phosphatase conjugate (dilution 1:100) was used as a
secondary antibody and nitro blue tetrazolium and 5-bromo-4-
chloro-3-indolyl phosphate as enzyme substrates. To determine
the number of T cells in the lesions, a CD3 staining was performed
using anti-mouse CD3 (clone SP7, dilution 1:50, Neomarkers,
Fremont, CA, USA). Morphology was studied using a Leica DM-
RE microscope and LeicaQwin software (Leica imaging systems,
Cambridge, UK). The percentages of collagen and macrophages
in the atherosclerotic lesions were determined by dividing the area
stained positive for collagen or Moma-2 by the total lesion surface
area.
Flow Cytometry
At sacrifice, blood and splenocytes were isolated (n = 5 per
group). Single cell suspensions were obtained as described above.
Cells were stained with fluorescent antibodies for CD11c, MHC-II
and CD40 to detect dendritic cells and to determine their
activation status. In a separate in vitro experiment, DCs were co-
cultured with CD4+ T cells in a 1:4 ratio and increasing
concentrations of agonistic anti-TIGIT. After 48 hours, prolifer-
ation of T cells was observed by 3H-thymidine incorporation and
DCs and T cells were separated from each other and stained with
fluorescent antibodies for CD11c/IL-10 and CD4/CD62L
respectively.
Spleen Cell Proliferation
At sacrifice, splenocytes (n = 5 per group) were cultured for 72
hours in quintuplicate in a 96-wells round-bottom plate (26105
cells/well) in RPMI 1640 supplemented with L-Glutamine,
100 U/ml streptomycin/penicillin and 10% FCS. As a positive
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control cells were stimulated with aCD3 and aCD28 (2 mg/ml).
Proliferation was measured as described above.
Statistical Analysis
All data are expressed as mean6SEM. A one-way ANOVA
with post test was performed to compare normally distributed data
between three groups of animals. Probability values of P,0.05
were considered significant.
Results
TIGIT is Upregulated on CD4+ T cells from Western-type
Diet Fed LDLr2/2 Mice
The coinhibitory molecule TIGIT is mainly expressed on T
cells and previous studies have shown that upon TCR stimulation
the number of TIGIT expressing CD4+ T cells increases. [3,4,5]
To investigate the effect of a high-fat diet on the surface expression
of TIGIT on CD4+ T cells, we isolated CD4+ T cells from spleens
of LDLr2/2 mice fed a chow diet or a cholesterol-rich Western-
type (WT) diet and performed a FACS analysis to determine
TIGIT expression. Upon WT diet feeding we observed an
increase in TIGIT-expressing CD4+ T cells when compared with
chow diet feeding (7,3% vs. 2,5%, respectively, Figure 1A). In
addition, we isolated splenocytes from chow diet fed mice (n = 3)
and Western-type diet fed mice (n = 3) and cultured them for 48
hours in the presence or absence of aCD3/aCD28 stimulation. As
shown in Figure 1B and 1C, Western-type diet feeding signifi-
cantly enhanced the percentage of TIGIT+ cells within the
unstimulated CD4+ T cell population (8.560.7%) in comparison
with chow diet feeding (3.760.9%, P,0.05). In addition, we show
that aCD3/aCD28 stimulation indeed increased the percentage of
TIGIT+ cells within the CD4+ T cells in both chow (10.161.3%,
P,0.05) and Western-type diet mice (16.462.3%, P,0.05).
Agonistic Anti-TIGIT Inhibits the Activation and
Proliferation of Splenocytes
Since TIGIT can directly inhibit T cell proliferation, we
determined ex vivo the capacity of the agonistic anti-TIGIT
antibody to impair T cell reactivity in our atherosclerosis mouse
model; LDLr2/2 mice fed a Western-type diet. We stimulated
splenocytes from Western-type diet fed mice for 72 hours with
aCD3/aCD28 in the presence or absence of different concentra-
tions of agonistic anti-TIGIT. As shown in Figure 2A and Figure
S1A, agonistic anti-TIGIT decreased the percentage of activated
T cells (P,0.01). Most importantly, splenocyte proliferation as
measured by the amount of 3H-thymidine incorporation (Figure 2B
and Figure S1B) and IL-2 secretion (Figure 2C), was strongly
inhibited in a dose-dependent manner upon excessive TIGIT
triggering when compared with the control condition (no IgG) or
Armenian hamster IgG.
Impaired T cell Function in Agonistic Anti-TIGIT-treated
Mice
To study the effect of TIGIT triggering on T cells in vivo,
LDLr2/2 mice (n = 9) were treated with an agonistic anti-TIGIT
antibody at day 0, 2, 4, 10, 17 and 24, while being fed a Western-
type diet for 4 weeks. As a control, mice were treated with
Armenian hamster IgG (n = 8) and PBS (n = 9). To determine the
proliferative capacity of T cells from agonistic anti-TIGIT-treated
mice in comparison with PBS and Armenian hamster IgG-treated
mice, splenocytes from all groups were cultured for 72 hours in the
presence of aCD3/aCD28. A significant 45% decrease in
splenocyte proliferation was observed in mice treated in vivo with
agonistic anti-TIGIT (stimulation index of 20.861.8) compared
with PBS mice (stimulation index of 37.460.8, P,0.01) and
hamster IgG mice (stimulation index of 38.263.2, P,0.001,
Figure 2D).
Agonistic Anti-TIGIT Treatment does not Affect Initial
Atherosclerosis Development
To determine whether the TIGIT-mediated impairment of T
cell function affects the development of early atherosclerosis (4
weeks of Western type diet), we measured atherosclerotic lesion
sizes upon agonistic anti-TIGIT treatment. As shown in Figure 3A,
no difference in atherosclerotic lesion size was observed after
agonistic anti-TIGIT treatment (1.4160.076105 mm2) in com-
parison with Armenian hamster IgG treatment
(1.4660.156105 mm2) or PBS (1.5960.136105 mm2). During the
experiment, agonistic anti-TIGIT treatment did not affect body
weight and total plasma cholesterol levels (data not shown).
Furthermore, collagen content did not significantly differ between
the three groups (PBS: 7.760.9%, Armenian hamster IgG:
7.061.2% and TIGIT: 5.561.0%, Figure 3B). In addition, the
percentage of macrophages in the lesions is comparable in all the
groups (PBS: 50.364.2%, Armenian hamster IgG: 47.764.9%
and agonistic anti-TIGIT: 53.263.5%, Figure 3C).
Figure 1. Upregulation of TIGIT expression on CD4+ T cells under hypercholesterolemic conditions. Representative FACS dot plots of
TIGIT surface expression on CD4+ T cells isolated from LDLr2/2 mice fed a Chow diet or a Western-type (WT) diet (A). Splenocytes from LDLr2/2 mice
fed a Chow diet (n = 3) and Western-type diet (n = 3) were cultured for 48 hours in the presence or absence of anti-CD3/anti-CD28. Representative dot
plots (B) and the mean percentage of TIGIT expressing CD4+ T cells in 4 different conditions (C) were obtained by flow cytometry. *P,0.05.
doi:10.1371/journal.pone.0083134.g001
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Increased Percentages and Activation of Dendritic Cells
in Agonistic Anti-TIGIT-treated Mice
Whereas agonistic anti-TIGIT treatment reduced T cell
proliferation, dendritic cells which are also involved in the
pathogenesis of atherosclerosis were elevated in these mice. As
shown in Figure 4A, agonistic anti-TIGIT treatment significantly
enhanced the percentage of dendritic cells (14.761.3%, P,0.05)
in the blood in comparison with Armenian hamster IgG and PBS
treatment (10.760.4% and 10.860.4%, respectively). Similar
results were observed in the spleen (Figure 4B), where agonistic
anti-TIGIT treatment enhanced the percentage of dendritic cells
(15.661.2%, P,0.05) in comparison with Armenian hamster IgG
Figure 2. Agonistic anti-TIGIT strongly inhibits T cell function. Splenocytes from Western-type diet fed mice (n = 3) were cultured for 72 hours
with aCD3/aCD28 in the presence or absence of agonistic anti-TIGIT (0–30 mg/ml). Activated T cells (CD4+CD25+) were determined with flow
cytometry (A). Proliferation was assessed by the amount of 3H-thymidine incorporation in dividing cells and is expressed as stimulation index (B) and
by the amount of IL-2 produced by the splenocytes as determined with ELISA (C). Splenocytes of PBS, Armenian Hamster IgG and agonistic anti-TIGIT-
treated mice (n = 5 per group) were cultured in the presence of aCD3/aCD28 stimulation and proliferation was assessed by the amount of 3H-
thymidine incorporation expressed as stimulation index (D). *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0083134.g002
Figure 3. Agonistic anti-TIGIT treatment does not reduce initial atherosclerotic lesion development. No difference in atherosclerotic
lesion size between agonistic anti-TIGIT, Armenian Hamster IgG and PBS treated LDLr2/2 mice fed a Western-type diet for 4 weeks. Representative
cross-sections of lesion formation in the three valves area of the aortic root stained with Oil-Red-O and hematoxylin are shown and lesion size was
determined (A). Sections of the aortic root were stained for collagen using Masson’s trichrome staining. The percentage of collagen relative to the
lesion size was determined (B). Furthermore, relative macrophage content was determined with a Moma-2 staining and quantified (C).
doi:10.1371/journal.pone.0083134.g003
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and PBS treatment (12.061.2 and 11.660.3%, respectively).
Moreover, their activation status as measured with MHCII and
CD40 is also elevated in agonistic anti-TIGIT-treated mice
compared with both control groups. On the other hand, we
observed a decrease in IL-10 expressing tolerogenic DCs when
splenocytes were cultured with increasing concentrations of
agonistic anti-TIGIT suggesting that the agonistic anti-TIGIT
treatment blocked the normal interaction between TIGIT and
PVR (P,0.05, Figure 4C).
Agonistic Anti-TIGIT Treatment does not Affect
Atherosclerosis after 8 Weeks of Western-type Diet
We also determined more advanced atherosclerotic lesion
development after 8 weeks of Western-type diet feeding in
combination with agonistic anti-TIGIT treatment during the first
24 days. Lesion size in the agonistic anti-TIGIT-treated mice
(n = 12, 5.1560.326105 mm2) was not affected compared with
lesion size in the Armenian hamster IgG-treated mice (n = 11,
5.1260.266105 mm2). In fact, both groups of antibody-treated
mice have 18% smaller atherosclerotic lesions compared with the
PBS group (n = 11, 6.2860.446105 mm2) although this did not
reach statistic significance (Figure 5A). Furthermore, no differenc-
es were observed in collagen content (PBS: 13.161.0%, hamster
IgG: 13.362.0% and agonistic anti-TIGIT: 11.161.5%,
Figure 5B) and macrophage content (PBS: 47.262.3%, IgG:
47.461.9% and agonistic anti-TIGIT: 47.962.6%, Figure 5C) of
the atherosclerotic lesions and although agonistic anti-TIGIT
reduced proliferation of T cells in the spleen, no effect was
observed on intimal and perivascular CD3+ T cells upon agonistic
anti-TIGIT treatment (Figure S2).
Discussion
The TIGIT/CD226 pathway has been associated with several
human autoimmune diseases [8] and studies in mice demonstrate
that interference in this pathway may be an attractive approach to
modulate autoimmune diseases. [3,4,5] In the present study we
determined the role of TIGIT in atherosclerosis.
Previous studies have shown that TIGIT is mainly expressed on
activated CD4+ T cells in both men and mice. [4,9] We have
previously shown that during the induction of atherosclerosis by
feeding a Western-type diet, T cells are activated. [10] We now
observe that TIGIT expression was upregulated on CD4+ T cells
in Western-type diet fed LDLr2/2 mice in comparison with chow
diet fed LDLr2/2 mice. The expression of TIGIT was further
enhanced after aCD3/aCD28 stimulation of isolated splenic T
cells. This increase in TIGIT surface expression has been
associated with a decrease in T cell proliferation in a number of
studies [4,9], while TIGIT deficiency remarkably increased T cell
proliferation in lymph nodes and spleen upon immunization. [4]
Since T cell activation is strongly correlated with the development
of atherosclerosis [11,12,13], we aimed to diminish T cell
responses by using an agonistic anti-TIGIT antibody which
triggers TIGIT signaling. First we showed that exposure of
splenocytes isolated from Western-type diet fed mice to agonistic
anti-TIGIT ex vivo greatly inhibited T cell activation and
proliferation, as measured by 3H-thymidine incorporation and
IL-2 secretion. In agreement with our in vitro data, LDLr2/2 mice
that received Western-type diet for 4 weeks and were treated with
the agonistic anti-TIGIT antibody, show a 45% decrease in
splenocyte proliferation in comparison with PBS and Hamster
IgG-treated mice.
Subsequently, we investigated whether agonistic anti-TIGIT
treatment can be beneficial for the development of atherosclerosis
since TIGIT-mediated dampening of T cell responses has been
associated with decreased susceptibility to several autoimmune
diseases. Levin et al. showed that administration of soluble TIGIT
inhibited the severity of collagen-induced arthritis by decreasing T
cell infiltration in the paws and by reducing T cell proliferation.
[5] Interestingly, both pro-inflammatory cytokines such as IL-6,
IL-17A and TNF-a, and anti-inflammatory cytokines such as IL-
10 were reduced in soluble TIGIT-treated mice. Furthermore,
TIGIT transgenic mice are protected against the development of
EAE [5], whereas TIGIT2/2 mice develop exacerbated EAE
through elevated T cell proliferation and increased IL-6, IFN-c,
and IL-17 secretion. [4] In addition, adoptive transfer of TIGIT-
deficient T cells accelerated GVHD in comparison with transfer of
wild-type T cells. [5] Surprisingly, the significant effect of the
TIGIT agonist on splenic T cell responses did not affect the
development of early and more advanced atherosclerosis (4 and 8
weeks of Western-type diet feeding respectively), as we observed no
significant differences in atherosclerotic lesion sizes between PBS,
Armenian hamster IgG and agonistic anti-TIGIT-treated mice.
Furthermore, in both atherosclerosis studies we did not observe
Figure 4. Enhanced dendritic cell percentages and activation and decreased IL-10 expressing dendritic cells after agonistic anti-
TIGIT treatment. At sacrifice, blood (A) and spleen (B) cells were isolated and stained for dendritic cells and activation markers and analyzed by flow
cytometry (n = 5 per group). The effect of agonistic anti-TIGIT on IL-10 expression by DCs was determined by culturing splenocytes with increasing
concentrations of agonistic anti-TIGIT (C). *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0083134.g004
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any differences in collagen, macrophage and T cell content of
these lesions.
Interestingly, the beneficial effect of the TIGIT agonist on
splenic T cell activity was accompanied by an activating effect on
DCs. Dendritic cells are potent antigen presenting cells and
numerous studies have shown the importance of DCs in the
development of atherosclerosis. The number of DCs increases with
the progression of atherosclerosis in ApoE2/2 mice [14,15] and
Wu et al. showed that CD11c2/2ApoE2/2 mice fed a Western-
type diet have reduced atherosclerosis with a concomitant
attenuation of lesional macrophages. [16] Additionally, Paulson
et al. showed that CD11c-diphtheria toxin receptor (DTR)
LDLr2/2 mice fed a cholesterol-rich diet for 5–10 days have a
55% reduced intimal lipid area in comparison with non-depleted
mice. [17] Therefore, increased percentages and activation of
dendritic cells in agonistic anti-TIGIT-treated mice can possibly
counter-act the diminished T cell activity in these mice and
thereby neutralize the effect on atherosclerosis. This more pro-
inflammatory phenotype of DCs in agonistic anti-TIGIT-treated
mice may be caused by the agonistic antibody which blocks the
normal interaction between TIGIT and PVR expressed on DCs
normally resulting in a tolerogenic phenotype of DCs. [5] This is
confirmed in the present study by the decrease in IL-10 producing
tolerogenic DCs after culturing splenocytes with increasing
concentrations of agonistic anti-TIGIT.
In conclusion, we showed that although triggering of the TIGIT
pathway decreases proliferation and activation of splenic T cells
both in vitro and in vivo, it does not affect atherosclerosis
development and local T cell numbers. Future research should
concentrate more on the role of TIGIT-PVR signaling, since the
generation of tolerogenic DCs in combination with intrinsic T cell
inhibition possibly does affect atherosclerosis.
Supporting Information
Figure S1 Agonistic anti-TIGIT strongly inhibits T cell
function. DCs and CD4+ T cells were isolated from Western-
type diet fed mice (n = 3) and were co-cultured in a 1:4 ratio for 48
hours with aCD3/aCD28 in the presence of agonistic anti-TIGIT
(30 mg/ml) or Armenian Hamster IgG (30 mg/ml). Activated T
cells (CD4+CD62Llow) were determined with flow cytometry (A).
Proliferation was assessed by the amount of 3H-thymidine
incorporation in dividing T cells and is expressed as stimulation
index (B). *P,0.05, ***P,0.001.
(TIF)
Figure S2 Agonistic anti-TIGIT treatment does not
affect CD3+ T cell numbers in atherosclerotic lesions.
LDLr2/2 mice fed a Western-type diet for 8 weeks were treated
intraperitoneally with PBS Armenian Hamster IgG or agonistic
anti-TIGIT. Representative cross-sections of lesion formation in
the three valves area of the aortic root were stained with anti-CD3
Figure 5. Agonistic anti-TIGIT treatment does not reduce more advanced atherosclerosis. Agonistic anti-TIGIT treatment (n = 12) and
Armenian Hamster IgG treatment (n = 11) reduces atherosclerosis development in LDLr2/2 mice fed a Western-type diet for 8 weeks in comparison
with PBS treatment (n = 12). Representative cross-sections of lesion formation in the three valves area of the aortic root stained with Oil-Red-O and
hematoxylin are shown and lesion size was determined (A). Sections of the aortic root were stained for collagen using Masson’s trichrome staining.
The percentage of collagen relative to the lesion size was determined (B). Furthermore, relative macrophage content was determined with a Moma-2
staining and quantified (C).
doi:10.1371/journal.pone.0083134.g005
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(A) to analyze effects on T cells in the intima (B) and perivascular
tissue (C) of atherosclerotic lesions.
(TIF)
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